Jubilant gets USFDA EIR for its Solid Dosage facility at Salisbury, Maryland USA
Noida: Jubilant Life Sciences Limited, an integrated global Pharmaceutical and Life Sciences Company, has announced that Jubilant Pharma Limited, a material wholly-owned subsidiary of the Company, through one of its wholly-owned subsidiaries, has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its Solid Dosage Facility at Salisbury, Maryland USA in respect of the inspection conducted by the regulatory agency from February 24, 2020, to February 28, 2020. With the receipt of the EIR, the inspection stands successfully closed.
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients, and Drug Discovery & Development Solutions businesses.
Pharma business, through Jubilant Pharma Limited, Singapore (JPL), is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada, and India.
The Life Science Ingredients segment is engaged in Specialty Intermediates, Nutritional Products, and Life Science Chemicals through five manufacturing facilities in India. Drug Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through Jubilant Biosys Limited & Jubilant Chemsys Limited and Proprietary Drug Discovery business through Jubilant Therapeutics.
DDS provides innovation and collaborative research through two world-class research centers in India and Jubilant Therapeutics is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders.